Recent research has provided significant information regarding the molecular and cellular basis for the development of hepatic fibrosis that can lead to cirrhosis, and need for liver transplantation. Our work in the prior funding period focused on the role of two key adipocytokines-leptin and adiponectin-in which we have convincingly demonstrated that leptin is clearly a pro-fibrogenic cytokine while adiponectin prohibits fibrosis. Our preliminary data and the current proposal are consistent with the long-term objectives of this laboratory: to understand basic mechanisms associated with chronic liver wound-healing. Adiponectin promotes a molecular environment in hepatic stellate cells (HSCs)-e.g. reduced tissue inhibitor of metalloproteinase I [TIMPI] expression that favors dissolution of dense extracellular matrix, the basis for the pathogenesis of cirrhosis. In vitro, adiponectin treated HSCs blocked leptin-mediated signal transduction that leads to pro-fibrogenic responses and required adiponectin receptor 1, but does not appear to depend entirely on adenosine monophosphate kinase (AMPK). The overall goal of the current proposal is to determine the potential mechanisms whereby adiponectin can promote resolution of hepatic fibrosis since there is evidence advanced fibrosis is reversible. The central hypothesis of this proposal is that adiponectin promotes the resolution of hepatic fibrosis by inhibiting activation of focal adhesion kinase (FAK), preventing formation of focal adhesions (FAs), which results in the suppression of key fibrogenic properties of the activated HSC. The central hypothesis will be tested by the following three hypothesis- driven specific aims:
SPECIFIC AIM 1 : To determine that adiponectin suppresses FAK activation thereby preventing formation of FAs in activated HSCs and inhibits genes associated with hepatic fibrosis. Preliminary data reveal adiponectin prevents phosphorylation of FAK by the protein tyrosine phosphatase, SHP-2;and adiponectin prevents FA assembly both in vitro and in vivo.
SPECIFIC AIM 2 : To demonstrate that adiponectin activation of activator protein 1 (AP-1) is the mechanism responsible for adiponectin's transcriptional activation of matrix metalloproteinases (MMPs) MMP-1/13;and, for inhibiting ?(I) collagen gene transcription through deactivation of FAK. Preliminary data demonstrate that adiponectin increases MMP-1/13 mRNA and respective promoter activity;but, small hairpin RNA against FAK (shFAK) blocks ?2(I) collagen gene expression in spite of the presence of globular adiponectin (gAd) in vitro.
SPECIFIC AIM 3 : To elucidate, by in vivo and ex vivo approaches, the mechanisms whereby adiponectin reverses HSC activation, promotes HSC senescence, and ultimately leads to resolution of fibrosis. Preliminary data indicate that while CCl4 treated adiponectin knock-out mice develop FAs as assessed by immunofluorescence, adenoviral delivery of adiponectin suppressed FA assembly;and, ex vivo, adiponectin markedly suppresses HSC- alpha smooth muscle actin (?-SMA) expression.

Public Health Relevance

Cirrhosis is a leading cause of death in the United States. Previously our work demonstrated that one hormone-like substance, leptin, can contribute to liver scar formation-which can lead to cirrhosis;while, another hormone-like substance, adiponectin, can help prevent or aide in resolving liver scar formation. The work proposed will provide a molecular basis for the use of adiponectin in drug development for liver scar formation that leads to cirrhosis.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Kumar, Pradeep; Smith, Tekla; Rahman, Khalidur et al. (2014) Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS One 9:e110405
Huang, Mianbo; Chang, Angela; Choi, Minna et al. (2014) Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model. Hepatology 60:1753-66
Mwangi, Simon Musyoka; Nezami, Behtash Ghazi; Obukwelu, Blessing et al. (2014) Glial cell line-derived neurotrophic factor protects against high-fat diet-induced obesity. Am J Physiol Gastrointest Liver Physiol 306:G515-25
Alisi, A; Bedogni, G; Baviera, G et al. (2014) Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 39:1276-85
Foster, Temitope; Anania, Frank A; Li, Dong et al. (2013) The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Dig Dis Sci 58:2392-8
Loria, Paola; Lonardo, Amedeo; Anania, Frank (2013) Liver and diabetes. A vicious circle. Hepatol Res 43:51-64
Selaru, Florin M; Anania, Frank A (2013) Connecting the dots from fatty acids to nonalcoholic steatohepatitis: epigenetics in the spotlight. Hepatology 58:486-7
Mells, Jamie E; Fu, Ping P; Sharma, Shvetank et al. (2012) Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 302:G225-35
Handy, Jeffrey A; Fu, Ping P; Kumar, Pradeep et al. (2011) Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 440:385-95
Anania, Frank A (2011) Non-alcoholic fatty liver disease and fructose: bad for us, better for mice. J Hepatol 55:218-20

Showing the most recent 10 out of 30 publications